Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial
- PMID: 20031735
- DOI: 10.1161/CIRCINTERVENTIONS.109.858977.109.858977
Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial
Abstract
Background: Coronary microvascular dysfunction is frequently seen in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Previous studies have suggested that the administration of intravenous adenosine resulted in an improvement of myocardial perfusion and a reduction in infarct size. Intracoronary adenosine (bolus of 30 to 60 microg) is a guideline-recommended therapy to improve myocardial reperfusion. The effect of intracoronary adenosine during primary percutaneous coronary intervention has not been investigated in a large randomized trial.
Methods and results: Patients presenting with acute ST-elevation myocardial infarction were randomized to 2 bolus injections of intracoronary adenosine (2 x 120 microg in 20 mL NaCl) or placebo (2 x 20 mL NaCl). The first bolus injection was given after thrombus aspiration and the second after stenting of the infarct-related artery. The primary end point was the incidence of residual ST-segment deviation <0.2 mV, 30 to 60 minutes after percutaneous coronary intervention. Secondary end points were ST-segment elevation resolution, myocardial blush grade, Thrombolysis in Myocardial Infarction flow on the angiogram after percutaneous coronary intervention, enzymatic infarct size, and clinical outcome at 30 days. A total of 448 patients were randomized to intracoronary adenosine (N=226) or placebo (N=222). The incidence of residual ST-segment deviation <0.2 mV did not differ between patients randomized to adenosine or placebo (46.2% versus 52.2%, P=NS). In addition, there were no significant differences in secondary outcome measures.
Conclusions: In this randomized placebo controlled trial enrolling 448 patients with ST-elevation myocardial infarction, administration of intracoronary adenosine after thrombus aspiration and after stenting of the infarct-related artery did not result in improved myocardial perfusion.
Comment in
-
Letter by Venetucci et al regarding article "Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial".Circ Cardiovasc Interv. 2009 Dec;2(6):e5; author reply e6. doi: 10.1161/CIRCINTERVENTIONS.109.912196. Circ Cardiovasc Interv. 2009. PMID: 20031762 No abstract available.
Similar articles
-
Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction).JACC Cardiovasc Interv. 2013 Jun;6(6):580-9. doi: 10.1016/j.jcin.2013.02.009. Epub 2013 May 15. JACC Cardiovasc Interv. 2013. PMID: 23683738 Clinical Trial.
-
Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.Circulation. 2010 Dec 21;122(25):2709-17. doi: 10.1161/CIRCULATIONAHA.110.002741. Epub 2010 Nov 15. Circulation. 2010. PMID: 21098442 Clinical Trial.
-
Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16. Circulation. 2008. PMID: 18559698 Clinical Trial.
-
Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials.Ther Adv Cardiovasc Dis. 2012 Jun;6(3):101-14. doi: 10.1177/1753944712446670. Epub 2012 May 4. Ther Adv Cardiovasc Dis. 2012. PMID: 22562999 Review.
-
Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials.Int J Cardiol. 2016 Jan 1;202:228-37. doi: 10.1016/j.ijcard.2015.09.005. Epub 2015 Sep 9. Int J Cardiol. 2016. PMID: 26402450 Free PMC article. Review.
Cited by
-
Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial).Circ Cardiovasc Interv. 2022 Feb;15(2):e011408. doi: 10.1161/CIRCINTERVENTIONS.121.011408. Epub 2022 Jan 10. Circ Cardiovasc Interv. 2022. PMID: 35000456 Free PMC article. Clinical Trial.
-
Spontaneous and procedural plaque embolisation in native coronary arteries: pathophysiology, diagnosis, and prevention.Scientifica (Cairo). 2013;2013:364247. doi: 10.1155/2013/364247. Epub 2013 Dec 19. Scientifica (Cairo). 2013. PMID: 24455430 Free PMC article. Review.
-
Proximal embolic protection in patients undergoing primary angioplasty for acute myocardial infarction (PREPARE): core lab adjudicated angiographic outcomes of a randomised controlled trial.Neth Heart J. 2010 Nov;18(11):531-6. doi: 10.1007/s12471-010-0829-7. Neth Heart J. 2010. PMID: 21113377 Free PMC article.
-
Adenosine as an Adjunctive Therapy for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Rev Cardiovasc Med. 2025 Feb 12;26(2):24065. doi: 10.31083/RCM24065. eCollection 2025 Feb. Rev Cardiovasc Med. 2025. PMID: 40026527 Free PMC article.
-
The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial.Trials. 2014 Sep 25;15:371. doi: 10.1186/1745-6215-15-371. Trials. 2014. PMID: 25252600 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous